✦ LIBER ✦

P2.101 Efflcacy and safety of preladenant, a novel A2A receptor antagonist, as a levodopa adjunct in patients with moderate-to-severe Parkinson's disease

✍ Scribed by R.A. Hauser; E. Pourcher; F. Micheli; V. Mok; M. Onofrj; S.B. Huyck; K.P. Wolski; M. Cantillon

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P2.136 Comparative efflcacy and safety o

✍ A. Ellenbogen; R. Hauser; O. Omidvar; A. Hsu; M. O'Connell; S. Kell; S. Gupta 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Efficacy and safety of AZD1981, a CRTH2

✍ Snell, Noel; Foster, Martyn; Vestbo, Jørgen 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 1022 KB

PND2 Dopamine Agonists and Dyskinesia in

✍ E. Senior; P. Dedeken; H. Naci 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

Safety, tolerability and efficacy of lec

✍ Booth, Kevin; Zhao, Yonggang; Hua, Yue; Wilks, Kerri; Solomon, Paul; Lucas, Pris 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Safety and tolerability of antagonist an

✍ A. KASRAN; L. BOON; C. H. WORTEL; R. A. van HOGEZAND; S. SCHREIBER; E. GOLDIN; M 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 340 KB

P2.202 Levodopa pharmacokinetics followi

✍ I.D. Stolyarov; S.N. Illarioshkin; C. Chen; S.Y.E. Hou; V.E. Cowles; M. Sweeney 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 58 KB